Yahoo · Aug 25, 2026
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
OTC · ELTP
Healthcare · Drug Manufacturers - Specialty & Generic
$0.25
Down-$0.01 (-2.76%)
Updated Sep 11, 2026, 12:11 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ELTP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ELTP.
ELTP research
Company profile and research snapshot.
ELITE PHARMS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Aug 25, 2026
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Yahoo · Aug 19, 2026
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
SeekingAlpha · Aug 14, 2026
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call August 14, 2026 11:30 AM EDTCompany ParticipantsNasrat Hakim - Chairman, CEO & PresidentCarter...
Yahoo · Aug 4, 2026
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ELTP.